Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.84% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
FATE · Jun 30, 2026
FATE THERAPEUTICS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-347988General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1123.92% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
9.18% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-1495.39% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1171.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
168.97% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History9 statesHistory building
Period transition
What moved in the state?
- Previous
- 18.40%
- Current
- 3.84%
- Delta
- -14.56%
- Previous
- -2372.75%
- Current
- -1123.92%
- Delta
- 1248.83%
- Previous
- -20.26%
- Current
- 9.18%
- Delta
- 29.43%
- Previous
- -2540.42%
- Current
- -1495.39%
- Delta
- 1045.03%
- Previous
- 1901.69%
- Current
- 1171.33%
- Delta
- -730.37%
- Previous
- 302.46%
- Current
- 168.97%
- Delta
- -133.49%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · FATE THERAPEUTICS INC →Transitioned To · FATE Fundamental State →Transitioned To · FATE CAPEX_INTENSITY_DECREASED →Transitioned To · FATE CASH_GENERATION_INCREASED →Transitioned To · FATE GROWTH_INCREASED →Transitioned To · FATE PROFITABILITY_INCREASED →Transitioned To · FATE R_AND_D_INTENSITY_DECREASED →Transitioned To · FATE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.